Savara to present new data on autoimmune pulmonary alveolar proteinosis (apap) at the american thoracic society (ats) international conference 2024

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the american thoracic society (ats) 2024 international conference, taking place may 17-22, 2024, in san diego, ca. “we look forward to seeing data presented at ats on the significant healthcare burden facing apap patients, challenges for diagnosis, and the development.
SVRA Ratings Summary
SVRA Quant Ranking